<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.1016/j.prp.2020.153086153086 : Article Can COVID 2019 induce a specific" exact="cardiovascular" post="damage or it exacerbates pre-existing cardiovascular diseases? MansuetoGelsominaMansueto.g@inwind.itgelsomina.mansueto@unicampania.ita*NiolaMassimobNapoliClaudioac[a], [b],"/>
 <result pre="2019 induce a specific cardiovascular damage or it exacerbates pre-existing" exact="cardiovascular" post="diseases? MansuetoGelsominaMansueto.g@inwind.itgelsomina.mansueto@unicampania.ita*NiolaMassimobNapoliClaudioac[a], [b], [c], â�ŽCorresponding author. Mansueto.g@inwind.itgelsomina.mansueto@unicampania.it pmc-release: 2020-6-6ppub:"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="as the COVID-19 resource centre remains active. Highlights â€¢SARS-CoV-2 causes" exact="acute" post="respiratory distress syndrome (ARDS) and multiple organ failure until"/>
 <result pre="the COVID-19 resource centre remains active. Highlights â€¢SARS-CoV-2 causes acute" exact="respiratory" post="distress syndrome (ARDS) and multiple organ failure until death."/>
 <result pre="resource centre remains active. Highlights â€¢SARS-CoV-2 causes acute respiratory distress" exact="syndrome" post="(ARDS) and multiple organ failure until death. â€¢Myocarditis, myocardial"/>
 <result pre="distress syndrome (ARDS) and multiple organ failure until death. â€¢Myocarditis," exact="myocardial infarction," post="arrhythmias, embolism, and DIC are the main complications in"/>
 <result pre="embolism, and DIC are the main complications in patients with" exact="cardiovascular" post="comorbidities. â€¢SARSCoV-2 can worsen the clinical status of patients"/>
 <result pre="â€¢SARSCoV-2 can worsen the clinical status of patients with pre-existing" exact="cardiovascular" post="diseases and this may interfere with therapies. Abstract A"/>
 <result pre="may interfere with therapies. Abstract A novel coronavirus SARS-CoV-2 causes" exact="acute" post="respiratory distress syndrome (ARDS) with cardiovascular and multiple organ"/>
 <result pre="interfere with therapies. Abstract A novel coronavirus SARS-CoV-2 causes acute" exact="respiratory" post="distress syndrome (ARDS) with cardiovascular and multiple organ failure"/>
 <result pre="therapies. Abstract A novel coronavirus SARS-CoV-2 causes acute respiratory distress" exact="syndrome" post="(ARDS) with cardiovascular and multiple organ failure till death."/>
 <result pre="novel coronavirus SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) with" exact="cardiovascular" post="and multiple organ failure till death. The main mechanisms"/>
 <result pre="activation, heme formation, and the immune response is responsible for" exact="infection" post="diffusion, endothelial dysfunction, vasoconstriction, oxidative damage and releasing of"/>
 <result pre="and releasing of inflammatory mediators. The main pathological findings are" exact="bilateral" post="interstitial pneumonia with diffuse alveolar damage (DAD). Because ACE"/>
 <result pre="of inflammatory mediators. The main pathological findings are bilateral interstitial" exact="pneumonia" post="with diffuse alveolar damage (DAD). Because ACE receptor is"/>
 <result pre="mediators. The main pathological findings are bilateral interstitial pneumonia with" exact="diffuse" post="alveolar damage (DAD). Because ACE receptor is also present"/>
 <result pre="myoglobin and the cytochromes, multiorgan damage occurs both primitive and" exact="secondary" post="to lung damage. More relevantly, myocarditis, acute myocardial infarction,"/>
 <result pre="both primitive and secondary to lung damage. More relevantly, myocarditis," exact="acute" post="myocardial infarction, thromboembolism, and disseminated intravasal coagulation (DIC) are"/>
 <result pre="primitive and secondary to lung damage. More relevantly, myocarditis, acute" exact="myocardial infarction," post="thromboembolism, and disseminated intravasal coagulation (DIC) are described as"/>
 <result pre="outcome. Here, we investigated the role of SARSCoV-2 on the" exact="cardiovascular" post="system and in patients with cardiovascular comorbidities, and possible"/>
 <result pre="of SARSCoV-2 on the cardiovascular system and in patients with" exact="cardiovascular" post="comorbidities, and possible drug interference on the heart. Keywords"/>
 <result pre="spreads from China all over the world. SARS-CoV-2 induced a" exact="disease" post="called COVID-19 by the World Health Organization (WHO) which"/>
 <result pre="is an RNA virus (family Coronaviridiae), similar to SARS-CoV (Severe" exact="Acute" post="Respiratory Syndrome Coronavirus) and MERS-CoV (Middle East Respiratory Syndrome"/>
 <result pre="an RNA virus (family Coronaviridiae), similar to SARS-CoV (Severe Acute" exact="Respiratory" post="Syndrome Coronavirus) and MERS-CoV (Middle East Respiratory Syndrome Coronavirus)"/>
 <result pre="RNA virus (family Coronaviridiae), similar to SARS-CoV (Severe Acute Respiratory" exact="Syndrome" post="Coronavirus) and MERS-CoV (Middle East Respiratory Syndrome Coronavirus) [1,2]."/>
 <result pre="SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) and MERS-CoV (Middle East" exact="Respiratory" post="Syndrome Coronavirus) [1,2]. The 3 main symptoms of COVID-19"/>
 <result pre="(Severe Acute Respiratory Syndrome Coronavirus) and MERS-CoV (Middle East Respiratory" exact="Syndrome" post="Coronavirus) [1,2]. The 3 main symptoms of COVID-19 are"/>
 <result pre="fever, cough, and shortness of breath. Less common symptoms are" exact="muscle" post="pain, anorexia, malaise, sore throat, nasal congestion, dyspnoea, and"/>
 <result pre="and 14 days. The clinical severity ranges widely from asymptomatic" exact="infection" post="to fatal disease. The involvement of the upper respiratory"/>
 <result pre="from asymptomatic infection to fatal disease. The involvement of the" exact="upper" post="respiratory district and lung is typical and primary. Radiological"/>
 <result pre="asymptomatic infection to fatal disease. The involvement of the upper" exact="respiratory" post="district and lung is typical and primary. Radiological features"/>
 <result pre="typical and primary. Radiological features include interstitial thickening, lung opacities," exact="lower" post="lobe predominance, and bronchiectasis; multifocal peripheral subpleural ground-glass opacification"/>
 <result pre="interstitial thickening, lung opacities, lower lobe predominance, and bronchiectasis; multifocal" exact="peripheral" post="subpleural ground-glass opacification or consolidation has been commonly observed"/>
 <result pre="or consolidation has been commonly observed CT feature up to" exact="pleural" post="and pericardial effusion, with symptoms ranging from flu syndrome"/>
 <result pre="has been commonly observed CT feature up to pleural and" exact="pericardial effusion," post="with symptoms ranging from flu syndrome to acute respiratory"/>
 <result pre="to pleural and pericardial effusion, with symptoms ranging from flu" exact="syndrome" post="to acute respiratory distress syndrome (ARDS), caused by diffuse"/>
 <result pre="and pericardial effusion, with symptoms ranging from flu syndrome to" exact="acute" post="respiratory distress syndrome (ARDS), caused by diffuse alveolar damage"/>
 <result pre="pericardial effusion, with symptoms ranging from flu syndrome to acute" exact="respiratory" post="distress syndrome (ARDS), caused by diffuse alveolar damage (DAD),"/>
 <result pre="with symptoms ranging from flu syndrome to acute respiratory distress" exact="syndrome" post="(ARDS), caused by diffuse alveolar damage (DAD), with cardiovascular"/>
 <result pre="flu syndrome to acute respiratory distress syndrome (ARDS), caused by" exact="diffuse" post="alveolar damage (DAD), with cardiovascular and multiple organ failure"/>
 <result pre="distress syndrome (ARDS), caused by diffuse alveolar damage (DAD), with" exact="cardiovascular" post="and multiple organ failure till death [[3], [4], [5]]."/>
 <result pre="failure till death [[3], [4], [5]]. A multicenter study evaluated" exact="pulmonary" post="and extrapulmonary manifestations such as hepatic and renal dysfunction,"/>
 <result pre="shows that the main risk factors of clinical behavior are" exact="diabetes" post="hypertension and coronary heart disease [6]. The mortality rate"/>
 <result pre="that the main risk factors of clinical behavior are diabetes" exact="hypertension" post="and coronary heart disease [6]. The mortality rate of"/>
 <result pre="main risk factors of clinical behavior are diabetes hypertension and" exact="coronary heart disease" post="[6]. The mortality rate of COVID-19 is estimated at"/>
 <result pre="risk factors of clinical behavior are diabetes hypertension and coronary" exact="heart" post="disease [6]. The mortality rate of COVID-19 is estimated"/>
 <result pre="factors of clinical behavior are diabetes hypertension and coronary heart" exact="disease" post="[6]. The mortality rate of COVID-19 is estimated at"/>
 <result pre="many deceased patients are old, with oncological, immunological, or dysfunctional" exact="systemic" post="diseases linked to the cardiovascular system; it also emerges"/>
 <result pre="with oncological, immunological, or dysfunctional systemic diseases linked to the" exact="cardiovascular" post="system; it also emerges that multi-organ complications take place"/>
 <result pre="that multi-organ complications take place in the lung infection, including" exact="cardiovascular" post="complications especially that often constitute the real cause of"/>
 <result pre="death. Here, we examine pathophysiological effects of SARS-CoV-2, on the" exact="cardiovascular" post="system as well as drug mechanisms with side effects"/>
 <result pre="system as well as drug mechanisms with side effects on" exact="cardiovascular" post="complications. 2 Pathogenesis It is important to focus that"/>
 <result pre="Pathogenesis It is important to focus that coronaviruses mainly infect" exact="epithelial" post="cells of the upper respiratory tract and pulmonary pneumocytes"/>
 <result pre="to focus that coronaviruses mainly infect epithelial cells of the" exact="upper" post="respiratory tract and pulmonary pneumocytes but also other types"/>
 <result pre="focus that coronaviruses mainly infect epithelial cells of the upper" exact="respiratory" post="tract and pulmonary pneumocytes but also other types of"/>
 <result pre="mainly infect epithelial cells of the upper respiratory tract and" exact="pulmonary" post="pneumocytes but also other types of epithelial cells such"/>
 <result pre="respiratory tract and pulmonary pneumocytes but also other types of" exact="epithelial" post="cells such as endothelial cells of arteries and veins,"/>
 <result pre="cells such as endothelial cells of arteries and veins, smooth" exact="muscle" post="cells, intestinal epithelium cells and immune cells [10,11] (1112)."/>
 <result pre="[15]] The interaction between SARS viruses and ACE which is" exact="localized" post="above all on the endothelium of the pulmonary capillaries,"/>
 <result pre="which is localized above all on the endothelium of the" exact="pulmonary" post="capillaries, causes alterations of the circulation with the variation"/>
 <result pre="cells through ACE2 receptors. The virus can act on the" exact="cardiovascular" post="system increases the risk of damage and sudden death"/>
 <result pre="main hypothesized mechanisms of interaction between the virus and the" exact="cardiovascular" post="system with the causes of damage most reported in"/>
 <result pre="the release of inflammation mediators, by direct action on the" exact="vascular" post="endothelium that acts on the determinism of hypercoagulability and"/>
 <result pre="by the immune response responsible in the first instance of" exact="myocarditis" post="with myocardial damage. The damage mediated by the proposed"/>
 <result pre="pathways, and green the main activation pathways both of the" exact="virus infection" post="modality, of the pathogenetic mechanisms of the damage, and"/>
 <result pre="and green the main activation pathways both of the virus" exact="infection" post="modality, of the pathogenetic mechanisms of the damage, and"/>
 <result pre="taking the drugs used in people with hypertension, diabetes, and" exact="vascular" post="disease. 2.1 Pulmonary infection and pathological findings Mainly, the"/>
 <result pre="used in people with hypertension, diabetes, and vascular disease. 2.1" exact="Pulmonary" post="infection and pathological findings Mainly, the SARS-CoV-2 is responsible"/>
 <result pre="in people with hypertension, diabetes, and vascular disease. 2.1 Pulmonary" exact="infection" post="and pathological findings Mainly, the SARS-CoV-2 is responsible for"/>
 <result pre="infection and pathological findings Mainly, the SARS-CoV-2 is responsible for" exact="bilateral" post="interstitial pneumonia with DAD and primary pulmonary hypertension from"/>
 <result pre="pathological findings Mainly, the SARS-CoV-2 is responsible for bilateral interstitial" exact="pneumonia" post="with DAD and primary pulmonary hypertension from direct alveolar"/>
 <result pre="SARS-CoV-2 is responsible for bilateral interstitial pneumonia with DAD and" exact="primary" post="pulmonary hypertension from direct alveolar and endothelial damage. The"/>
 <result pre="is responsible for bilateral interstitial pneumonia with DAD and primary" exact="pulmonary" post="hypertension from direct alveolar and endothelial damage. The morphological"/>
 <result pre="responsible for bilateral interstitial pneumonia with DAD and primary pulmonary" exact="hypertension" post="from direct alveolar and endothelial damage. The morphological changes"/>
 <result pre="represented in the first phase by an interstitial inflammatory infiltrate," exact="diffuse" post="vascular congestion, edema, and subsequently from proteinaceous edema with"/>
 <result pre="in the first phase by an interstitial inflammatory infiltrate, diffuse" exact="vascular" post="congestion, edema, and subsequently from proteinaceous edema with or"/>
 <result pre="true signs of direct damage. The foci of reactive alveolar" exact="epithelial" post="hyperplasia, fibroblastic proliferation with fibrosis, and of alveolar rupture"/>
 <result pre="as a consequence [16]. These changes in the parenchyma induce" exact="primary" post="pulmonary hypertension due to an increase in lung resistance"/>
 <result pre="a consequence [16]. These changes in the parenchyma induce primary" exact="pulmonary" post="hypertension due to an increase in lung resistance and"/>
 <result pre="consequence [16]. These changes in the parenchyma induce primary pulmonary" exact="hypertension" post="due to an increase in lung resistance and overload"/>
 <result pre="right and left circulation. The clinical manifestation is characterized by" exact="systemic" post="hypertension and ventricular hypertrophy, as it happens in all"/>
 <result pre="and left circulation. The clinical manifestation is characterized by systemic" exact="hypertension" post="and ventricular hypertrophy, as it happens in all lung"/>
 <result pre="systemic hypertension and ventricular hypertrophy, as it happens in all" exact="lung diseases" post="from direct damage with increased of resistance. 2.2 Cardiovascular"/>
 <result pre="higher in all influenza pandemics than in all other causes." exact="Acute" post="respiratory viral infections, such as coronaviruses are well known"/>
 <result pre="in all influenza pandemics than in all other causes. Acute" exact="respiratory" post="viral infections, such as coronaviruses are well known to"/>
 <result pre="all influenza pandemics than in all other causes. Acute respiratory" exact="viral" post="infections, such as coronaviruses are well known to trigger"/>
 <result pre="such as coronaviruses are well known to trigger factors for" exact="cardiovascular disease" post="(CVD) [17]. During COVID-19 pandemic, the literature produced in"/>
 <result pre="as coronaviruses are well known to trigger factors for cardiovascular" exact="disease" post="(CVD) [17]. During COVID-19 pandemic, the literature produced in"/>
 <result pre="present comorbidities. The most prevalent comorbidity were hypertension, diabetes, and" exact="cardiovascular" post="diseases [18,19]. Compared to lung, data concerning cardiovascular involvement"/>
 <result pre="diabetes, and cardiovascular diseases [18,19]. Compared to lung, data concerning" exact="cardiovascular" post="involvement are less described [20]. This makes it difficult"/>
 <result pre="draw a line between complications of comorbidity and possible direct" exact="cardiovascular" post="damage by COVID-19. There are autopsy data relating to"/>
 <result pre="damage by COVID-19. There are autopsy data relating to the" exact="infection" post="produced by SARS CoV in 2003 and by MERS-CoV"/>
 <result pre="2012 that can help better understand the involvement of the" exact="cardiovascular" post="system. However, these data are affected by the difficulty"/>
 <result pre="patients who died of SARS in which 4 patients had" exact="pulmonary" post="thromboembolism and 3 patients with deep vein thrombosis. One"/>
 <result pre="which 4 patients had pulmonary thromboembolism and 3 patients with" exact="deep vein thrombosis." post="One patient had a subendocardial infarction with occlusive coronary"/>
 <result pre="vein thrombosis. One patient had a subendocardial infarction with occlusive" exact="coronary artery disease." post="One patient had valve vegetations along with heart attack,"/>
 <result pre="thrombosis. One patient had a subendocardial infarction with occlusive coronary" exact="artery disease." post="One patient had valve vegetations along with heart attack,"/>
 <result pre="coronary artery disease. One patient had valve vegetations along with" exact="heart" post="attack, kidney, spleen, and brain [21]. The reported presence"/>
 <result pre="had valve vegetations along with heart attack, kidney, spleen, and" exact="brain" post="[21]. The reported presence of increased D-Dimer and alteration"/>
 <result pre="mortality between the COVID and nonâˆ’COVID groups both with underlying" exact="chronic" post="diseases including hypertension, diabetes, heart disease, and lung disease,"/>
 <result pre="nonâˆ’COVID groups both with underlying chronic diseases including hypertension, diabetes," exact="heart" post="disease, and lung disease, and antiplatelet therapy and D-Dimer"/>
 <result pre="with underlying chronic diseases including hypertension, diabetes, heart disease, and" exact="lung disease," post="and antiplatelet therapy and D-Dimer evaluation. In the COVID"/>
 <result pre="antiplatelet therapy and D-Dimer evaluation. In the COVID group, significantly" exact="lower" post="mortality was found in users of heparin with markedly"/>
 <result pre="receptor of SARS viruses which is present mainly in the" exact="epithelial" post="cells of the upper respiratory district, in pulmonary endothelium"/>
 <result pre="which is present mainly in the epithelial cells of the" exact="upper" post="respiratory district, in pulmonary endothelium and pulmonary alveolar pneumocytes,"/>
 <result pre="is present mainly in the epithelial cells of the upper" exact="respiratory" post="district, in pulmonary endothelium and pulmonary alveolar pneumocytes, but"/>
 <result pre="in the epithelial cells of the upper respiratory district, in" exact="pulmonary" post="endothelium and pulmonary alveolar pneumocytes, but also present in"/>
 <result pre="cells of the upper respiratory district, in pulmonary endothelium and" exact="pulmonary" post="alveolar pneumocytes, but also present in other cell types"/>
 <result pre="also present in other cell types in different organs as" exact="heart" post="and kidneys [12]. It is possible to hypothesize direct"/>
 <result pre="is difficult to distinguish between death from direct cardiac or" exact="systemic" post="vascular damage induced by SARS-CoV-2 in patients without comorbidity"/>
 <result pre="difficult to distinguish between death from direct cardiac or systemic" exact="vascular" post="damage induced by SARS-CoV-2 in patients without comorbidity and"/>
 <result pre="in patients without comorbidity and death in patients with previous" exact="cardiovascular disease." post="Because the pandemic infection broke out in a very"/>
 <result pre="death in patients with previous cardiovascular disease. Because the pandemic" exact="infection" post="broke out in a very short time, there are"/>
 <result pre="disease. Because the pandemic infection broke out in a very" exact="short" post="time, there are no large autopsy studies able to"/>
 <result pre="able to shed light on the real damage to the" exact="cardiovascular" post="system in subjects who died from COVID-19 [24,25]. Can"/>
 <result pre="subjects who died from COVID-19 [24,25]. Can SARS-CoV-2 induce new" exact="heart" post="conditions or can it only exacerbate pre-existing cardiovascular diseases?"/>
 <result pre="induce new heart conditions or can it only exacerbate pre-existing" exact="cardiovascular" post="diseases? We believe that attention must be paid to"/>
 <result pre="coronary syndrome, thromboembolism. 2.2.1 Myocarditis Only a few cases with" exact="myocarditis" post="and pericarditis involvement were reported, without consistent histological evidence"/>
 <result pre="thromboembolism. 2.2.1 Myocarditis Only a few cases with myocarditis and" exact="pericarditis" post="involvement were reported, without consistent histological evidence [26,27]. It"/>
 <result pre="evidence [26,27]. It is clear that in a condition of" exact="myocarditis" post="during COVID-19, with inflammatory infiltrate and myocardial necrosis according"/>
 <result pre="inflammatory infiltrate and myocardial necrosis according to Dallas criteria [28]," exact="ventricular dysfunction," post="arrhythmias, and sudden cardiac death can occur as occurs"/>
 <result pre="cardiac death can occur as occurs in enterovirus or adenovirus" exact="myocarditis" post="due to an exuberant inflammatory response in subjects without"/>
 <result pre="response in subjects without pre-existing diseases. Only one case of" exact="cardiac tamponade" post="in a 47-year-old man SARS-CoV-2 infected without cardiovascular risk"/>
 <result pre="of cardiac tamponade in a 47-year-old man SARS-CoV-2 infected without" exact="cardiovascular" post="risk is reported in the literature as a complication"/>
 <result pre="risk is reported in the literature as a complication of" exact="myocarditis" post="and pericarditis [29]. The causes of hydropericardium and cardiac"/>
 <result pre="reported in the literature as a complication of myocarditis and" exact="pericarditis" post="[29]. The causes of hydropericardium and cardiac tamponade also"/>
 <result pre="of myocarditis and pericarditis [29]. The causes of hydropericardium and" exact="cardiac tamponade" post="also include infectious and inflammatory causes (15 %) and"/>
 <result pre="[29]. The causes of hydropericardium and cardiac tamponade also include" exact="infectious" post="and inflammatory causes (15 %) and mechanical complications of"/>
 <result pre="infectious and inflammatory causes (15 %) and mechanical complications of" exact="myocardial infarction" post="(12 %) [30]. Our autoptic experience leads us to"/>
 <result pre="in children and in young adults with undiagnosed or underestimated" exact="viral" post="infections [31]. Patients who died for complications of COVID-19"/>
 <result pre="children and in young adults with undiagnosed or underestimated viral" exact="infections" post="[31]. Patients who died for complications of COVID-19 are"/>
 <result pre="of COVID-19 are old and have often comorbidity due to" exact="cardiovascular" post="diseases. We can, therefore, hypothesize that myocarditis with the"/>
 <result pre="comorbidity due to cardiovascular diseases. We can, therefore, hypothesize that" exact="myocarditis" post="with the presence of inflammatory infiltrates in the myocardial"/>
 <result pre="laboratory markers of damage and cardiac necrosis, can be a" exact="secondary" post="complication of the immune response and not of the"/>
 <result pre="of ACE2 in different cell types and also in the" exact="heart" post="[12], we can only hypothesize a hematogenous diffusion of"/>
 <result pre="lung; the hypothesis remains that the SARS-CoV-2 action on the" exact="heart" post="in old people is mediated by systemic imbalance caused"/>
 <result pre="action on the heart in old people is mediated by" exact="systemic" post="imbalance caused by the alteration of the functioning of"/>
 <result pre="of the functioning of the RAAS on comorbidity background. 2.2.2" exact="Acute" post="myocardial infarction and myocardial structural damage The hypothesis that"/>
 <result pre="the functioning of the RAAS on comorbidity background. 2.2.2 Acute" exact="myocardial infarction" post="and myocardial structural damage The hypothesis that influenza viruses"/>
 <result pre="myocardial structural damage The hypothesis that influenza viruses can trigger" exact="myocardial infarction" post="has long been known [32,33]. Large and more recent"/>
 <result pre="[32,33]. Large and more recent studies have reported that previous" exact="myocardial infarction," post="diabetes, dyslipidaemias, hypertension, and other cardiovascular risk factors can"/>
 <result pre="reported that previous myocardial infarction, diabetes, dyslipidaemias, hypertension, and other" exact="cardiovascular" post="risk factors can predispose to an acute ischemic event"/>
 <result pre="hypertension, and other cardiovascular risk factors can predispose to an" exact="acute" post="ischemic event in respiratory virus infections such as recently"/>
 <result pre="risk factors can predispose to an acute ischemic event in" exact="respiratory" post="virus infections such as recently reported during the pandemic"/>
 <result pre="can predispose to an acute ischemic event in respiratory virus" exact="infections" post="such as recently reported during the pandemic COVID-19 [[34],"/>
 <result pre="[35], [36]]. A cohort study compared patients with and without" exact="heart" post="damage and analyzed the association between heart damage and"/>
 <result pre="with and without heart damage and analyzed the association between" exact="heart" post="damage and mortality. The results of the study showed"/>
 <result pre="showed that out of 416 hospitalized patients, 19.7 % had" exact="heart" post="damage, and, compared to patients without heart damage, these"/>
 <result pre="19.7 % had heart damage, and, compared to patients without" exact="heart" post="damage, these patients were older with comorbidity, leukocytosis, high"/>
 <result pre="and mortality in patients with COVID-19 were significantly associated [37]." exact="Heart" post="damage patients had higher mortality than those without heart"/>
 <result pre="[37]. Heart damage patients had higher mortality than those without" exact="heart" post="damage. Another study evaluated the association of underlying cardiovascular"/>
 <result pre="without heart damage. Another study evaluated the association of underlying" exact="cardiovascular disease" post="(CVD) and myocardial injury with fatal outcomes in patients"/>
 <result pre="heart damage. Another study evaluated the association of underlying cardiovascular" exact="disease" post="(CVD) and myocardial injury with fatal outcomes in patients"/>
 <result pre="favorable. A percentage of 35.3 had underlying CVD including hypertension," exact="coronary artery disease," post="and cardiomyopathy, and 27.8 % showed myocardial damage as"/>
 <result pre="A percentage of 35.3 had underlying CVD including hypertension, coronary" exact="artery disease," post="and cardiomyopathy, and 27.8 % showed myocardial damage as"/>
 <result pre="[38]. This data favor the role of the pre-existence of" exact="disease" post="as a risk factor and of high mortality in"/>
 <result pre="which is expressed in different cell types and the kidney" exact="and heart," post="a mechanism of direct damage to cardiomyocytes is conceivable"/>
 <result pre="mechanism of direct damage to cardiomyocytes is conceivable but the" exact="systemic" post="inflammatory responses, destabilized coronary plaque and aggravated hypoxia constitute"/>
 <result pre="but the systemic inflammatory responses, destabilized coronary plaque and aggravated" exact="hypoxia" post="constitute now the only obvious modes of heart damage"/>
 <result pre="and aggravated hypoxia constitute now the only obvious modes of" exact="heart" post="damage (Fig. 1). The induction of an abnormal inflammatory"/>
 <result pre="abnormal inflammatory state is the first cardinal point implicated in" exact="cardiovascular" post="complications and acute myocardial infarct responsible for the death."/>
 <result pre="is the first cardinal point implicated in cardiovascular complications and" exact="acute" post="myocardial infarct responsible for the death. Already in previous"/>
 <result pre="the first cardinal point implicated in cardiovascular complications and acute" exact="myocardial infarct" post="responsible for the death. Already in previous SARS-CoV epidemics,"/>
 <result pre="-1, IL-6 e IL-12, IFNÎ³, IP10 e MCP1), associated with" exact="lung inflammation" post="and extensive lung damage as well as in patients"/>
 <result pre="IL10) that suppress inflammation [40]. The inflammatory state can aggravate" exact="acute" post="coronary syndrome with myocardial infarction until sudden death. It"/>
 <result pre="suppress inflammation [40]. The inflammatory state can aggravate acute coronary" exact="syndrome" post="with myocardial infarction until sudden death. It is crucial"/>
 <result pre="[40]. The inflammatory state can aggravate acute coronary syndrome with" exact="myocardial infarction" post="until sudden death. It is crucial to emphasize that"/>
 <result pre="and autopsy studies could provide information to understand the disease." exact="Acute" post="myocardial infarction has been indicated as a complication, as"/>
 <result pre="autopsy studies could provide information to understand the disease. Acute" exact="myocardial infarction" post="has been indicated as a complication, as well as"/>
 <result pre="troponin. The clinical data do not explain the type of" exact="heart" post="damage. The increase in cardiac troponin is a marker"/>
 <result pre="it is fundamental to be able to distinguish in the" exact="heart" post="between necrosis from hypoxic, ischemic damage, myocarditis and direct"/>
 <result pre="distinguish in the heart between necrosis from hypoxic, ischemic damage," exact="myocarditis" post="and direct virus damage, or other cardiomyopathies responsible for"/>
 <result pre="myocarditis and direct virus damage, or other cardiomyopathies responsible for" exact="heart" post="failure and sudden death. There is currently no evidence"/>
 <result pre="diagnostic criteria. 2.2.3 Thromboembolism It is known that patients with" exact="cardiovascular disease" post="have a higher risk of a thrombo-embolic event as"/>
 <result pre="criteria. 2.2.3 Thromboembolism It is known that patients with cardiovascular" exact="disease" post="have a higher risk of a thrombo-embolic event as"/>
 <result pre="of a thrombo-embolic event as it is known that all" exact="viral" post="infections have a potential role in disseminated intravascular coagulation"/>
 <result pre="a thrombo-embolic event as it is known that all viral" exact="infections" post="have a potential role in disseminated intravascular coagulation (DIC)"/>
 <result pre="known that all viral infections have a potential role in" exact="disseminated intravascular coagulation" post="(DIC) The endothelial damage, the blood flow turbulence, and"/>
 <result pre="mechanism. Some clinical studies have highlighted that SARS-CoV-2 positive and" exact="symptomatic" post="patients have more thrombus-embolic and DIC risk. There is"/>
 <result pre="of D-dimer and fibrin degradation, longer prothrombin times, and activated" exact="partial" post="thromboplastin time in hospitalized patients with severe COVID-19 and"/>
 <result pre="event is however detected in patients with underlying diseases including" exact="cardiovascular disease." post="Vascular inflammation and hemodynamic instability can contribute to the"/>
 <result pre="however detected in patients with underlying diseases including cardiovascular disease." exact="Vascular" post="inflammation and hemodynamic instability can contribute to the hypercoagulable"/>
 <result pre="dysfunction resulting in thromboembolism or DIC in patients with underlying" exact="cardiovascular" post="diseases. Also, in this case the literature is deficient"/>
 <result pre="with COVID-19, aged 40â€&quot;60 years, have comorbidities such as CVD," exact="hypertension" post="and atherosclerotic cardiovascular disease and have shown that a"/>
 <result pre="aged 40â€&quot;60 years, have comorbidities such as CVD, hypertension and" exact="atherosclerotic cardiovascular disease" post="and have shown that a predisposition to acute cardiac"/>
 <result pre="40â€&quot;60 years, have comorbidities such as CVD, hypertension and atherosclerotic" exact="cardiovascular disease" post="and have shown that a predisposition to acute cardiac"/>
 <result pre="years, have comorbidities such as CVD, hypertension and atherosclerotic cardiovascular" exact="disease" post="and have shown that a predisposition to acute cardiac"/>
 <result pre="atherosclerotic cardiovascular disease and have shown that a predisposition to" exact="acute" post="cardiac complications related to comorbidities already in this age"/>
 <result pre="already in this age group [45] Although clinical studies are" exact="limited" post="by the short time and the absence of an"/>
 <result pre="age group [45] Although clinical studies are limited by the" exact="short" post="time and the absence of an autoptic finding, some"/>
 <result pre="clinical studies are limited by the short time and the" exact="absence of" post="an autoptic finding, some meta-analyses have identified a movement"/>
 <result pre="risk with the increase in average age and patients whit" exact="cardiovascular" post="comorbidities such as diabetes, hypertension and coronary disease [18]."/>
 <result pre="average age and patients whit cardiovascular comorbidities such as diabetes," exact="hypertension" post="and coronary disease [18]. A high proportion of severe"/>
 <result pre="patients whit cardiovascular comorbidities such as diabetes, hypertension and coronary" exact="disease" post="[18]. A high proportion of severe to critical cases"/>
 <result pre="in the elderly patients (aged 71 Â± 8 years), with" exact="hypertension" post="(40.8 %), diabetes (16.0 %), and cardiovascular disease (15.7"/>
 <result pre="patients (aged 71 Â± 8 years), with hypertension (40.8 %)," exact="diabetes" post="(16.0 %), and cardiovascular disease (15.7 %) [46]. Hemodynamic"/>
 <result pre="8 years), with hypertension (40.8 %), diabetes (16.0 %), and" exact="cardiovascular disease" post="(15.7 %) [46]. Hemodynamic heart failure by severe respiratory"/>
 <result pre="years), with hypertension (40.8 %), diabetes (16.0 %), and cardiovascular" exact="disease" post="(15.7 %) [46]. Hemodynamic heart failure by severe respiratory"/>
 <result pre="diabetes (16.0 %), and cardiovascular disease (15.7 %) [46]. Hemodynamic" exact="heart" post="failure by severe respiratory syndrome, hypercoagulability by sepsis and"/>
 <result pre="cardiovascular disease (15.7 %) [46]. Hemodynamic heart failure by severe" exact="respiratory" post="syndrome, hypercoagulability by sepsis and endothelial dysfunction, inflammatory state,"/>
 <result pre="are trigger factors that in patients over 60 years with" exact="cardiovascular" post="comorbidities induce a greater risk of heart damage, thromboembolism"/>
 <result pre="60 years with cardiovascular comorbidities induce a greater risk of" exact="heart" post="damage, thromboembolism and disseminated intravascular coagulation (DIC) with inauspicious"/>
 <result pre="comorbidities induce a greater risk of heart damage, thromboembolism and" exact="disseminated intravascular coagulation" post="(DIC) with inauspicious prognosis and death. 4 Immunocompromised subjects"/>
 <result pre="of COVID-19 is increased in these patients. Clinical studies in" exact="cancer" post="patients report a higher risk of infection than in"/>
 <result pre="Clinical studies in cancer patients report a higher risk of" exact="infection" post="than in a non-cancerous population (median age 66 years)"/>
 <result pre="with HMG-CoA reductase inhibitors (statins) due to the risk of" exact="rhabdomyolysis" post="[61]. Favipiravir (Avigan) is an anti-influenza virus that selectively"/>
 <result pre="EBOLAV, MERS-CoV, and SARS-CoV with controversial results and in the" exact="absence of" post="reported cardiovascular toxicity. It was the first drug used"/>
 <result pre="SARS-CoV with controversial results and in the absence of reported" exact="cardiovascular" post="toxicity. It was the first drug used in SARS-CoV2."/>
 <result pre="has been used for years as components of treatment for" exact="hepatitis C" post="[55], has broad-spectrum activities against viruses including MERS-CoV, SARS-CoV-2"/>
 <result pre="(HCQ) was originally developed and used for the treatment of" exact="malaria" post="and it is increasingly used in the management of"/>
 <result pre="is increasingly used in the management of a variety of" exact="autoimmune" post="disorders, with well-established roles in dermatology and rheumatology and"/>
 <result pre="function, influencing the processing of antigenic peptides necessary to trigger" exact="autoimmune" post="responses [64,65]; and has to interfere with heme which"/>
 <result pre="interfere with heme which is essential for the parasite [66]." exact="Retinopathy" post="and some cardiac effects such as bundle-branch block, ventricular"/>
 <result pre="[66]. Retinopathy and some cardiac effects such as bundle-branch block," exact="ventricular tachycardia," post="and cardiomyopathy often with hypertrophy, restrictive physiology, and congestive"/>
 <result pre="some cardiac effects such as bundle-branch block, ventricular tachycardia, and" exact="cardiomyopathy" post="often with hypertrophy, restrictive physiology, and congestive heart failure"/>
 <result pre="ventricular tachycardia, and cardiomyopathy often with hypertrophy, restrictive physiology, and" exact="congestive heart failure" post="are known [67]. Recently these drugs have attracted intense"/>
 <result pre="tachycardia, and cardiomyopathy often with hypertrophy, restrictive physiology, and congestive" exact="heart" post="failure are known [67]. Recently these drugs have attracted"/>
 <result pre="sample size, it showed a reduction or disappearance of the" exact="viral" post="load in COVID -19 patients. It also showed that"/>
 <result pre="The authors documented the efficacy of hydroxychloroquine in reducing the" exact="viral" post="load at day 7. Although the use of HCQ"/>
 <result pre="Although the use of HCQ is now approved in many" exact="autoimmune" post="and inflammatory systemic diseases, and in oncology, and although"/>
 <result pre="of HCQ is now approved in many autoimmune and inflammatory" exact="systemic" post="diseases, and in oncology, and although it has also"/>
 <result pre="dose above the median and structural ECG abnormalities (left ventricular" exact="hypertrophy" post="or atrial enlargement) was reported; however, it is not"/>
 <result pre="the odds of ECG conduction abnormalities (prolonged corrected QT interval," exact="short" post="PR interval, left bundle branch block (LBBB), right bundle"/>
 <result pre="QT interval, short PR interval, left bundle branch block (LBBB)," exact="right bundle branch block" post="(RBBB) and atrioventricular block (AVB), premature atrial complex, tachycardia,"/>
 <result pre="bundle branch block (LBBB), right bundle branch block (RBBB) and" exact="atrioventricular block" post="(AVB), premature atrial complex, tachycardia, bradycardia, atrial fibrillation, ectopic"/>
 <result pre="(RBBB) and atrioventricular block (AVB), premature atrial complex, tachycardia, bradycardia," exact="atrial fibrillation," post="ectopic atrial rhythm, premature ventricular complex and ventricular bigeminy"/>
 <result pre="with an efficiency of nearly 97 % [77]. Used in" exact="cystic fibrosis," post="is has an anti-fibrotic effect by targeting myofibroblast cells"/>
 <result pre="as rifampicin. Clinical trials indicate that the risk of ventricular" exact="arrhythmia" post="with the use of azithromycin is likely to be"/>
 <result pre="QT interval prolongation is not observed in the association between" exact="chronic" post="AZM therapy [[81], [82], [83], [84], [85]]. ACE2 is"/>
 <result pre="which anti-RAAS inhibitor drugs work to reduce the risk of" exact="cardiovascular disease" post="due to hypertension and diabetes. Concerning cardiovascular risk in"/>
 <result pre="anti-RAAS inhibitor drugs work to reduce the risk of cardiovascular" exact="disease" post="due to hypertension and diabetes. Concerning cardiovascular risk in"/>
 <result pre="work to reduce the risk of cardiovascular disease due to" exact="hypertension" post="and diabetes. Concerning cardiovascular risk in positive SARS-CoV-2 subjects"/>
 <result pre="risk of cardiovascular disease due to hypertension and diabetes. Concerning" exact="cardiovascular" post="risk in positive SARS-CoV-2 subjects taking antihypertensive and hypoglycaemic"/>
 <result pre="confusing. Contrary, some authors indicate overexpression of ACE2 in SARS-CoV-2" exact="infection" post="[86,87], which we could explain as a rebound effect"/>
 <result pre="expressed in different cell types and also in the kidney" exact="and heart," post="but mainly in the lung as well as ACE"/>
 <result pre="anti-RAAS or ACE inhibitors have a higher risk of SARS-CoV-2" exact="infection" post="or that they have a higher cardiovascular risk. Furthermore,"/>
 <result pre="risk of SARS-CoV-2 infection or that they have a higher" exact="cardiovascular" post="risk. Furthermore, an up-regulation would favor greater treatment efficacy"/>
 <result pre="authors suggest the protective role of ace inhibitors against SARS-CoV-2" exact="infection" post="as opposed to others. However, we still have doubts"/>
 <result pre="insulin secretion, there is little data on the development of" exact="acute" post="diabetes complications in patients with Sars-CoV-2 disease. Statins inhibit"/>
 <result pre="secretion, there is little data on the development of acute" exact="diabetes" post="complications in patients with Sars-CoV-2 disease. Statins inhibit the"/>
 <result pre="of endogenous cholesterol by acting on the enzyme hydroxymethylglutaryl-CoA reductase." exact="Cholesterol" post="plays important role in the entry of viruses into"/>
 <result pre="viruses into cells and statins are reported to block the" exact="infection" post="of many enveloped viruses by inhibiting the cholesterol pathway"/>
 <result pre="the cholesterol pathway [89,90]. The use of statins in EBOLA" exact="virus infection" post="is described as a protective factor [91,92]. Besides, for"/>
 <result pre="cholesterol pathway [89,90]. The use of statins in EBOLA virus" exact="infection" post="is described as a protective factor [91,92]. Besides, for"/>
 <result pre="This data suggest the protective effect of statins in SARS-CoV" exact="infections" post="although few [89,92,95]. 6 Conclusions The main mechanisms of"/>
 <result pre="myoglobin and the cytochromes, multiorgan damage occurs both primitive and" exact="secondary" post="to lung damage. The absence of important predisposing factors"/>
 <result pre="damage occurs both primitive and secondary to lung damage. The" exact="absence of" post="important predisposing factors in COVID-19 pneumonia seems to confirm"/>
 <result pre="lung damage. The absence of important predisposing factors in COVID-19" exact="pneumonia" post="seems to confirm the role of serious infections as"/>
 <result pre="in COVID-19 pneumonia seems to confirm the role of serious" exact="infections" post="as a precipitating factor for acute thromboembolism and heart"/>
 <result pre="the role of serious infections as a precipitating factor for" exact="acute" post="thromboembolism and heart failure through the inflammatory state and"/>
 <result pre="of serious infections as a precipitating factor for acute thromboembolism" exact="and heart" post="failure through the inflammatory state and dysregulation of the"/>
 <result pre="serious infections as a precipitating factor for acute thromboembolism and" exact="heart" post="failure through the inflammatory state and dysregulation of the"/>
 <result pre="state and dysregulation of the immune response. The presence of" exact="cardiovascular" post="comorbidities seems to aggravate the prognosis until death by"/>
 <result pre="aggravate the prognosis until death by myocarditis, coronary syndromes, and" exact="diffuse" post="thromboembolism or DIC. No large autopsy studies able to"/>
 <result pre="able to shed light on the real damage to the" exact="cardiovascular" post="system in subjects who died from COVID-19 and our"/>
 <result pre="say that anti-RAAS, ACE inhibitors, statins increase the risk of" exact="cardiovascular" post="damage in COVID patients. The role of anticoagulants can"/>
 <result pre="role of anticoagulants can be useful especially in people with" exact="cardiovascular disease." post="HQC therapy appears to be effective and the risks"/>
 <result pre="HQC therapy appears to be effective and the risks for" exact="cardiovascular" post="complications are related to the long-term cumulative dose. Sources"/>
 <result pre="and C.N. gave the final approval. References References 1ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.TsoiH.W.LoS.K.ChanK.H.PoonV.K.ChanW.M.IpJ.D.CaiJ.P.Cheng ChenV.C.H.HuiC.K.YuenK.Y.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="the final approval. References References 1ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.TsoiH.W.LoS.K.ChanK.H.PoonV.K.ChanW.M.IpJ.D.CaiJ.P.Cheng ChenV.C.H.HuiC.K.YuenK.Y.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="batsEmerg. Microbes Infect.7September 12 (1)201815410.1038/s41426-018-0155-530209269 3ChenL.LiX.ChenM.FengY.XiongC.The ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
 <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc. Res.30202010.1093/cvr/cvaa078March pii: cvaa078"/>
 <result pre="Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in ChinaN. Engl. J. Med.28202010.1056/NEJMoa2002032Feb 7XiongY.LiuY.CaoL.WangD.GuoM.JiangA.GuoD.HuW.YangJ.TangZ.WuH.LinY.ZhangM.ZhangQ.ShiM.LiuY.ZhouY.LanK.ChenY.Transcriptomic characteristics of"/>
 <result pre="Engl. J. Med.28202010.1056/NEJMoa2002032Feb 7XiongY.LiuY.CaoL.WangD.GuoM.JiangA.GuoD.HuW.YangJ.TangZ.WuH.LinY.ZhangM.ZhangQ.ShiM.LiuY.ZhouY.LanK.ChenY.Transcriptomic characteristics of bronchoalveolar lavage fluid and" exact="peripheral" post="blood mononuclear cells in COVID-19 patientsEmerg. Microbes Infect.9December (1)202076177010.1080/22221751.2020.174736332228226"/>
 <result pre="patientsEmerg. Microbes Infect.9December (1)202076177010.1080/22221751.2020.174736332228226 8MadjidM.Safavi-NaeiniP.SolomonS.D.VardenyO.Potential effects of coronaviruses on the" exact="cardiovascular" post="system: a reviewJAMA Cardiol.27202010.1001/jamacardio.2020.1286March 9CDC COVID-19 Response TeamSevere Outcomes"/>
 <result pre="Cardiol.27202010.1001/jamacardio.2020.1286March 9CDC COVID-19 Response TeamSevere Outcomes Among Patients with Coronavirus" exact="Disease" post="2019 (COVID-19) - United States, February 12-March 16, 2020MMWR"/>
 <result pre="Receptor Blockers: What Is the Evidence?JAMA.24202010.1001/jama.2020.4812Mar 16FranksT.J.ChongP.Y.ChuiP.GalvinJ.R.LourensR.M.ReidA.H.SelbsE.McEvoyC.P.HaydenC.D.FukuokaJ.TaubenbergerJ.K.TravisW.D.Lung pathology of severe" exact="acute" post="respiratory syndrome (SARS): a study of 8 autopsy cases"/>
 <result pre="Blockers: What Is the Evidence?JAMA.24202010.1001/jama.2020.4812Mar 16FranksT.J.ChongP.Y.ChuiP.GalvinJ.R.LourensR.M.ReidA.H.SelbsE.McEvoyC.P.HaydenC.D.FukuokaJ.TaubenbergerJ.K.TravisW.D.Lung pathology of severe acute" exact="respiratory" post="syndrome (SARS): a study of 8 autopsy cases from"/>
 <result pre="What Is the Evidence?JAMA.24202010.1001/jama.2020.4812Mar 16FranksT.J.ChongP.Y.ChuiP.GalvinJ.R.LourensR.M.ReidA.H.SelbsE.McEvoyC.P.HaydenC.D.FukuokaJ.TaubenbergerJ.K.TravisW.D.Lung pathology of severe acute respiratory" exact="syndrome" post="(SARS): a study of 8 autopsy cases from SingaporeHum."/>
 <result pre="Pathol.34August (8)2003743748Erratum in: Hum Pathol. 2004 Jan;35(1):13814506633 17MadjidM.MillerC.C.ZarubaevV.V.MarinichI.G.KiselevO.I.LobzinY.V.FilippovA.E.CasscellsS.W.3rdInfluenza epidemics and" exact="acute" post="respiratory disease activity are associated with a surge in"/>
 <result pre="(8)2003743748Erratum in: Hum Pathol. 2004 Jan;35(1):13814506633 17MadjidM.MillerC.C.ZarubaevV.V.MarinichI.G.KiselevO.I.LobzinY.V.FilippovA.E.CasscellsS.W.3rdInfluenza epidemics and acute" exact="respiratory" post="disease activity are associated with a surge in autopsy-confirmed"/>
 <result pre="in: Hum Pathol. 2004 Jan;35(1):13814506633 17MadjidM.MillerC.C.ZarubaevV.V.MarinichI.G.KiselevO.I.LobzinY.V.FilippovA.E.CasscellsS.W.3rdInfluenza epidemics and acute respiratory" exact="disease" post="activity are associated with a surge in autopsy-confirmed coronary"/>
 <result pre="respiratory disease activity are associated with a surge in autopsy-confirmed" exact="coronary heart disease" post="death:results from 8 years of autopsies in 34,892 subjectsEur."/>
 <result pre="disease activity are associated with a surge in autopsy-confirmed coronary" exact="heart" post="disease death:results from 8 years of autopsies in 34,892"/>
 <result pre="activity are associated with a surge in autopsy-confirmed coronary heart" exact="disease" post="death:results from 8 years of autopsies in 34,892 subjectsEur."/>
 <result pre="disease death:results from 8 years of autopsies in 34,892 subjectsEur." exact="Heart" post="J.28May(10)20071205121017440221 18LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and impact of cardiovascular metabolic diseases on"/>
 <result pre="autopsies in 34,892 subjectsEur. Heart J.28May(10)20071205121017440221 18LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and impact of" exact="cardiovascular" post="metabolic diseases on CO.VID-19 in ChinaClin. Res. Cardiol.11202010.1007/s00392-020-01626-9March 19YangJ.ZhengY.GouX.PuK.ChenZ.GuoQ.JiR.WangH.WangY.ZhouY.Prevalence"/>
 <result pre="in 34,892 subjectsEur. Heart J.28May(10)20071205121017440221 18LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and impact of cardiovascular" exact="metabolic diseases" post="on CO.VID-19 in ChinaClin. Res. Cardiol.11202010.1007/s00392-020-01626-9March 19YangJ.ZhengY.GouX.PuK.ChenZ.GuoQ.JiR.WangH.WangY.ZhouY.Prevalence of comorbidities"/>
 <result pre="gravePostgrad. Med. J.82964200614014410.1136/pgmj.2005.03751516461478 21ChongP.Y.ChuiP.LingA.E.FranksT.J.TaiD.Y.LeoY.S.KawG.J.WansaicheongG.ChanK.P.Ean OonL.L.TeoE.S.TanK.B.NakajimaN.SataT.TravisW.D.Analysis of deaths during the severe" exact="acute" post="respiratory syndrome (SARS) epidemic in Singapore: challenges in determining"/>
 <result pre="Med. J.82964200614014410.1136/pgmj.2005.03751516461478 21ChongP.Y.ChuiP.LingA.E.FranksT.J.TaiD.Y.LeoY.S.KawG.J.WansaicheongG.ChanK.P.Ean OonL.L.TeoE.S.TanK.B.NakajimaN.SataT.TravisW.D.Analysis of deaths during the severe acute" exact="respiratory" post="syndrome (SARS) epidemic in Singapore: challenges in determining a"/>
 <result pre="J.82964200614014410.1136/pgmj.2005.03751516461478 21ChongP.Y.ChuiP.LingA.E.FranksT.J.TaiD.Y.LeoY.S.KawG.J.WansaicheongG.ChanK.P.Ean OonL.L.TeoE.S.TanK.B.NakajimaN.SataT.TravisW.D.Analysis of deaths during the severe acute respiratory" exact="syndrome" post="(SARS) epidemic in Singapore: challenges in determining a SARS"/>
 <result pre="Med.128February (2)2004195204PubMed PMID: 1473628314736283 22YinY.HuangM.LiD.TangN.Difference of coagulation features between severe" exact="pneumonia" post="induced by SARS-CoV2 and non-SARS-CoV2J. Thromb. Thrombolysis3202010.1007/s11239-020-02105-8Apr 23WenzhongL.HualanL.COVID-19:Attacks the1-beta"/>
 <result pre="the Porphyrin to Inhibit Human Heme MetabolismChemRxiv202010.26434/chemrxiv.11938173.v7Preprint 24GoldhaberS.Z.SavageD.D.GarrisonR.J.CastelliW.P.KannelW.B.McNamaraP.M.GherardiG.FeinleibM.Risk factors for" exact="pulmonary" post="embolismFramingham Study. Am J Med.74June (6)1983102310286859053 25MansuetoG.CostaD.CapassoE.VaravalloF.BrunittoG.CasertaR.EspositoS.NiolaM.SarduC.MarfellaR.NapoliC.PaternosterM.The dating of"/>
 <result pre="Med.74June (6)1983102310286859053 25MansuetoG.CostaD.CapassoE.VaravalloF.BrunittoG.CasertaR.EspositoS.NiolaM.SarduC.MarfellaR.NapoliC.PaternosterM.The dating of thrombus organization in cases of" exact="pulmonary" post="embolism: an autopsy studyBMC Cardiovasc. Disord.19November 8 (1)201925010.1186/s12872-019-1219-831703628 26InciardiR.M.LupiL.ZacconeG.ItaliaL.RaffoM.TomasoniD.CaniD.S.CeriniM.FarinaD.GavazziE.MaroldiR.AdamoM.AmmiratiE.SinagraG.LombardiC.M.MetraM.Cardiac"/>
 <result pre="Disord.19November 8 (1)201925010.1186/s12872-019-1219-831703628 26InciardiR.M.LupiL.ZacconeG.ItaliaL.RaffoM.TomasoniD.CaniD.S.CeriniM.FarinaD.GavazziE.MaroldiR.AdamoM.AmmiratiE.SinagraG.LombardiC.M.MetraM.Cardiac Involvement in a Patient With Coronavirus" exact="Disease" post="2019 (COVID-19)JAMA Cardiol.27202010.1001/jamacardio.2020.1096Mar 27XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.TaiY.BaiC.GaoT.SongJ.XiaP.DongJ.ZhaoJ.WangF.S.Pathological findings of COVID-19 associated with"/>
 <result pre="Disease 2019 (COVID-19)JAMA Cardiol.27202010.1001/jamacardio.2020.1096Mar 27XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.TaiY.BaiC.GaoT.SongJ.XiaP.DongJ.ZhaoJ.WangF.S.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.18202010.1016/S2213-2600(20)30076-XFeb pii: S2213-2600(20)30076-X 28AretzH.T.BillinghamM.E.EdwardsW.D.FactorS.M.FallonJ.T.FenoglioJ.J.Jr.OlsenE.G.SchoenF.J.Myocarditis. A"/>
 <result pre="2019 (COVID-19)JAMA Cardiol.27202010.1001/jamacardio.2020.1096Mar 27XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.TaiY.BaiC.GaoT.SongJ.XiaP.DongJ.ZhaoJ.WangF.S.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.18202010.1016/S2213-2600(20)30076-XFeb pii: S2213-2600(20)30076-X 28AretzH.T.BillinghamM.E.EdwardsW.D.FactorS.M.FallonJ.T.FenoglioJ.J.Jr.OlsenE.G.SchoenF.J.Myocarditis. A histopathologic"/>
 <result pre="28AretzH.T.BillinghamM.E.EdwardsW.D.FactorS.M.FallonJ.T.FenoglioJ.J.Jr.OlsenE.G.SchoenF.J.Myocarditis. A histopathologic definition and classificationAm J Cardiovasc Pathology11987314 29HuaA.Oâ€™GallagherK.SadoD.ByrneJ.Life-threatening" exact="cardiac tamponade" post="complicating myo-pericarditis in COVID-19Eur. Heart J.30202010.1093/eurheartj/ehaa253Mar pii:ehaa253 30OrbachA.SchliamserJ.E.FlugelmanM.Y.ZafrirB.Contemporary evaluation"/>
 <result pre="J Cardiovasc Pathology11987314 29HuaA.Oâ€™GallagherK.SadoD.ByrneJ.Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19Eur." exact="Heart" post="J.30202010.1093/eurheartj/ehaa253Mar pii:ehaa253 30OrbachA.SchliamserJ.E.FlugelmanM.Y.ZafrirB.Contemporary evaluation of the causes of cardiac"/>
 <result pre="J.30202010.1093/eurheartj/ehaa253Mar pii:ehaa253 30OrbachA.SchliamserJ.E.FlugelmanM.Y.ZafrirB.Contemporary evaluation of the causes of cardiac tamponade:" exact="acute" post="and long-term outcomesCardiol. J.2312016576310.5603/CJ.a2015.004126202654 31LyngeT.H.NielsenT.S.Gregers WinkelB.Tfelt-HansenJ.BannerJ.Sudden cardiac death caused"/>
 <result pre="and long-term outcomesCardiol. J.2312016576310.5603/CJ.a2015.004126202654 31LyngeT.H.NielsenT.S.Gregers WinkelB.Tfelt-HansenJ.BannerJ.Sudden cardiac death caused by" exact="myocarditis" post="in persons aged 1-49 years: a nationwide study of"/>
 <result pre="19 (3)201924725610.1080/20961790.2019.159535231489390 32MattioliA.V.Ballerini PuvianiM.NasiM.FarinettiA.COVID-19 pandemic: the effects of quarantine on" exact="cardiovascular" post="riskEur. J. Clin. Nutr.5202010.1038/s41430-020-0646-zMay 33FosterE.D.CavanaughJ.E.HaynesW.G.YangM.GerkeA.K.TangF.PolgreenP.M.Acute myocardial infarctions, strokes and"/>
 <result pre="strokes and influenza: seasonal and pandemic effectsEpidemiol. Infect.141April (4)201373574410.1017/S095026881200289023286343 34KwongJ.C.SchwartzK.L.CampitelliM.A.ChungH.CrowcroftN.S.KarnauchowT.KatzK.KoD.T.McGeerA.J.McNallyD.RichardsonD.C.RosellaL.C.SimorA.SmiejaM.ZahariadisG.GubbayJ.B.Acute" exact="myocardial infarction" post="after laboratory-confirmed influenza infectionN. Engl. J. Med.378January 25 (4)201834535310.1056/NEJMoa170209029365305"/>
 <result pre="35YangX.YuY.XuJ.ShuH.XiaJ.LiuH.WuY.ZhangL.YuZ.FangM.YuT.WangY.PanS.ZouX.YuanS.ShangY.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir."/>
 <result pre="36FauciA.S.LaneH.C.RedfieldR.R.Covid-19 - navigating the unchartedN. Engl. J. Med.38220201268126910.1056/NEJMe200238732109011 37ShiS.QinM.ShenB.CaiY.LiuT.YangF.GongW.LiuX.LiangJ.ZhaoQ.HuangH.YangB.HuangC.Association of" exact="Cardiac" post="Injury With Mortality in Hospitalized Patients With COVID-19 in"/>
 <result pre="Cardiol.25202010.1001/jamacardio.2020.0950Mar 38GuoT.FanY.ChenM.WuX.ZhangL.HeT.WangH.WanJ.WangX.LuZ.Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus" exact="Disease" post="2019 (COVID-19JAMA Cardiol.27202010.1001/jamacardio.2020.1017Mar 39WongC.K.LamC.W.WuA.K.IpW.K.LeeN.L.ChanI.H.LitL.C.HuiD.S.ChanM.H.ChungS.S.SungJ.J.Plasma inflammatory cytokines and chemokines in"/>
 <result pre="2019 (COVID-19JAMA Cardiol.27202010.1001/jamacardio.2020.1017Mar 39WongC.K.LamC.W.WuA.K.IpW.K.LeeN.L.ChanI.H.LitL.C.HuiD.S.ChanM.H.ChungS.S.SungJ.J.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin. Exp. Immunol.136April (1)20049510315030519 40HuangC.WangY.LiX.RenL.ZhaoJ.HuY.ZhangL.FanG.XuJ.GuX.ChengZ.YuT.XiaJ.WeiY.WuW.XieX.YinW.LiH.LiuM.XiaoY.GaoH.GuoL.XieJ.WangG.JiangR.GaoZ.JinQ.WangJ.CaoB.Clinical features of patients"/>
 <result pre="(COVID-19JAMA Cardiol.27202010.1001/jamacardio.2020.1017Mar 39WongC.K.LamC.W.WuA.K.IpW.K.LeeN.L.ChanI.H.LitL.C.HuiD.S.ChanM.H.ChungS.S.SungJ.J.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin. Exp. Immunol.136April (1)20049510315030519 40HuangC.WangY.LiX.RenL.ZhaoJ.HuY.ZhangL.FanG.XuJ.GuX.ChengZ.YuT.XiaJ.WeiY.WuW.XieX.YinW.LiH.LiuM.XiaoY.GaoH.GuoL.XieJ.WangG.JiangR.GaoZ.JinQ.WangJ.CaoB.Clinical features of patients infected"/>
 <result pre="Li Xue Za Zhi49March 15 (0)202010.3760/cma.j.cn112151-20200312-0019349E009 42WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.ZhangY.SongJ.WangS.ChaoY.YangZ.XuJ.ZhouX.ChenD.XiongW.XuL.ZhouF.JiangJ.BaiC.ZhengJ.SongY.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
 <result pre="Xue Za Zhi49March 15 (0)202010.3760/cma.j.cn112151-20200312-0019349E009 42WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.ZhangY.SongJ.WangS.ChaoY.YangZ.XuJ.ZhouX.ChenD.XiongW.XuL.ZhouF.JiangJ.BaiC.ZhengJ.SongY.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="Zhi49March 15 (0)202010.3760/cma.j.cn112151-20200312-0019349E009 42WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.ZhangY.SongJ.WangS.ChaoY.YangZ.XuJ.ZhouX.ChenD.XiongW.XuL.ZhouF.JiangJ.BaiC.ZhengJ.SongY.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019Pneumonia in"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019Pneumonia in Wuhan, ChinaJAMA Intern. Med.13202010.1001/jamainternmed.2020.0994Mar 43TangN.LiD.WangX.SunZ.Abnormal coagulation parameters"/>
 <result pre="disseminataThromb. Haemost.86520011327133011816725 45VuorioA.WattsG.F.KovanenP.T.Familial hypercholesterolemia and COVID-19: triggering of increased sustained" exact="cardiovascular" post="riskJ. Intern. Med.3202010.1111/joim.13070Apr 46WangL.HeW.YuX.HuD.BaoM.LiuH.ZhouJ.JiangH.Coronavirus disease 2019 in elderly patients:"/>
 <result pre="COVID-19: triggering of increased sustained cardiovascular riskJ. Intern. Med.3202010.1111/joim.13070Apr 46WangL.HeW.YuX.HuD.BaoM.LiuH.ZhouJ.JiangH.Coronavirus" exact="disease" post="2019 in elderly patients: characteristics and prognostic factors based"/>
 <result pre="4-week follow-upJ. Infect.30202010.1016/j.jinf.2020.03.019March pii: S0163-4453(20)30146-30148 47YuJ.OuyangW.ChuaM.I.L.K.XieC.SARS-CoV-2 Transmission in Patients With" exact="Cancer" post="at a Tertiary Care Hospital in Wuhan, ChinaJAMA Oncol.25202010.1001/jamaoncol.2020.0980Mar"/>
 <result pre="Hospital in Wuhan, ChinaJAMA Oncol.25202010.1001/jamaoncol.2020.0980Mar 48SpezzaniV.PiunnoA.IselinH.U.Benign COVID-19 in an immunocompromised" exact="cancer" post="patient - the case of a married coupleSwiss Med.11April"/>
 <result pre="of a married coupleSwiss Med.11April 150202010.4414/smw.2020.20246w20246 49FurutaY.GowenB.B.TakahashiK.ShirakiK.SmeeD.F.BarnardD.L.Favipiravir (T-705), a novel" exact="viral" post="RNA polymerase inhibitorAntiviral Res.100November (2)201344645410.1016/j.antiviral.2013.09.01524084488 50DuY.X.ChenX.P.Favipiravir: pharmacokinetics and concerns"/>
 <result pre="Pharmacol. Ther.4202010.1002/cpt.1844Apr 51ZhangC.HuangS.ZhengF.DaiY.Controversial treatments: an updated understanding of the Coronavirus" exact="Disease" post="2019J. Med. Virol.26202010.1002/jmv.25788Mar 52ElfikyA.A.Anti-HCV, nucleotide inhibitors, repurposing against COVID-19Life"/>
 <result pre="consortium study team. A randomized, controlled trial of ebola virus" exact="disease" post="therapeuticsN. Engl. J. Med.381December 12 (24)20192293230310.1056/NEJMoa191099331774950 54HolshueM.L.DeBoltC.LindquistS.LofyK.H.WiesmanJ.BruceH.SpittersC.EricsonK.WilkersonS.TuralA.DiazG.CohnA.FoxL.PatelA.GerberS.I.KimL.TongS.LuX.LindstromS.PallanschM.A.WeldonW.C.BiggsH.M.UyekiT.M.PillaiS.K.Washington State 2019-nCoV"/>
 <result pre="(10)202092993610.1056/NEJMoa200119132004427 55KhaykinP.KotzerkeP.StephanC.NisiusG.BickelM.HaberlA.StÃ¼rmerM.KurowskiM.BrodtR.von HentigN.Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and" exact="hepatitis" post="B or C coinfected adults without symptoms of hepatic"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of Lopinavir/Ritonavir for the treatment"/>
 <result pre="the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCRJ. Korean Med. Sci.35February 17 (6)2020e7910.3346/jkms.2020.35.e7932056407"/>
 <result pre="initial virological and clinical findingsThorax59March (3)200425225614985565 60SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic Treatments for Coronavirus" exact="Disease" post="2019 (COVID-19): A ReviewJAMA13202010.1001/jama.2020.6019Apr 61MorganR.E.CampbellS.E.SuehiraK.SponsellerC.A.YuC.Y.MedlockM.M.Effects of steady-state lopinavir/ritonavir on"/>
 <result pre="of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy" exact="adult" post="volunteersJ. Acquir. Immune Defic. Syndr.60Junuary1(2)201215816410.1097/QAI.0b013e318251addb22627182 62AlarcÃ³nG.S.McGwinG.BertoliA.M.FesslerB.J.Calvo-AlÃ©nJ.BastianH.M.VilÃ¡L.M.ReveilleJ.D.LUMINA Study GroupEffect of"/>
 <result pre="Study GroupEffect of hydroxychloroquine on the survival of patients with" exact="systemic" post="lupus erythematosus: data from LUMINA, a multiethnic US cohort"/>
 <result pre="GroupEffect of hydroxychloroquine on the survival of patients with systemic" exact="lupus" post="erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA"/>
 <result pre="Dis.6620071168117217389655 63WillisR.SeifA.M.Jr McGwinG.Martinez-MartinezL.A.GonzÃ¡lezE.B.DangN.PapalardoE.LiuJ.VilÃ¡L.M.ReveilleJ.D.AlarcÃ³nG.S.PierangeliS.S.Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and" exact="disease" post="activity in SLE patients: data from LUMINA (LXXV), a"/>
 <result pre="formation, resulting in chloroquine resistanceJ. Exp. Med.212June 1 (6)201589390310.1084/jem.2014173125941254 67TÃ¶nnesmannE.KandolfR.LewalterT.Chloroquine" exact="cardiomyopathy" post="- a review of the literatureImmunopharmacol. Immunotoxicol.35June (3)201343444210.3109/08923973.2013.78007823635029 68GaoJ.TianZ.YangX.Breakthrough:"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci. Trends14March 16 (1)2020727310.5582/bst.2020.0104732074550 69BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.De ClercqE.Design nd"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.9202010.1093/cid/ciaa237Mar pii: ciaa237"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.9202010.1093/cid/ciaa237Mar pii: ciaa237 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.9202010.1093/cid/ciaa237Mar pii: ciaa237 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine"/>
 <result pre="clinical trialInt. J. Antimicrob. Agents20202010594910.1016/j.ijantimicag.2020.105949Mar 72PetriM.Use of hydroxychloroquine to prevent" exact="thrombosis" post="in systemic lupus erythematosus and in antiphospholipid antibody-positive patientsCurr."/>
 <result pre="J. Antimicrob. Agents20202010594910.1016/j.ijantimicag.2020.105949Mar 72PetriM.Use of hydroxychloroquine to prevent thrombosis in" exact="systemic" post="lupus erythematosus and in antiphospholipid antibody-positive patientsCurr. Rheumatol. Rep.13February"/>
 <result pre="Antimicrob. Agents20202010594910.1016/j.ijantimicag.2020.105949Mar 72PetriM.Use of hydroxychloroquine to prevent thrombosis in systemic" exact="lupus erythematosus" post="and in antiphospholipid antibody-positive patientsCurr. Rheumatol. Rep.13February (1)2011778010.1007/s11926-010-0141-y20978875 73WhiteN.J.Cardiotoxicity"/>
 <result pre="74WozniackaA.CygankiewiczI.ChudzickM.The cardiac safety of chloroquine phosphate treatment in patients with" exact="systemic" post="lupus erythematosus: the influence on arrhythmia, heart rate variability"/>
 <result pre="cardiac safety of chloroquine phosphate treatment in patients with systemic" exact="lupus" post="erythematosus: the influence on arrhythmia, heart rate variability and"/>
 <result pre="in patients with systemic lupus erythematosus: the influence on arrhythmia," exact="heart" post="rate variability and repolarization parametersLupus15200652152516942005 75McGhieT.K.HarveyP.SuJ.AndersonN.TomlinsonG.ToumaZ.Electrocardiogram abnormalities related to"/>
 <result pre="variability and repolarization parametersLupus15200652152516942005 75McGhieT.K.HarveyP.SuJ.AndersonN.TomlinsonG.ToumaZ.Electrocardiogram abnormalities related to anti-malarials in" exact="systemic" post="lupus erythematosusClin. Exp. Rheumatol.36July-August (4)201854555129652656 76CairoliE.DaneseN.TelizM.BruzzoneM.J.FerreiraJ.RebellaM.CayotaA.Cumulative dose of hydroxychloroquine"/>
 <result pre="and repolarization parametersLupus15200652152516942005 75McGhieT.K.HarveyP.SuJ.AndersonN.TomlinsonG.ToumaZ.Electrocardiogram abnormalities related to anti-malarials in systemic" exact="lupus" post="erythematosusClin. Exp. Rheumatol.36July-August (4)201854555129652656 76CairoliE.DaneseN.TelizM.BruzzoneM.J.FerreiraJ.RebellaM.CayotaA.Cumulative dose of hydroxychloroquine is"/>
 <result pre="dose of hydroxychloroquine is associated with a decrease of resting" exact="heart" post="rate in patients with systemic lupus erythematosus: a pilot"/>
 <result pre="with a decrease of resting heart rate in patients with" exact="systemic" post="lupus erythematosus: a pilot studyLupus2420151204120910.1177/096120331558087025852050 77OzsvariB.NuttallJ.R.SotgiaF.LisantiM.P.Azithromycin and Roxithromycin define"/>
 <result pre="a decrease of resting heart rate in patients with systemic" exact="lupus" post="erythematosus: a pilot studyLupus2420151204120910.1177/096120331558087025852050 77OzsvariB.NuttallJ.R.SotgiaF.LisantiM.P.Azithromycin and Roxithromycin define a"/>
 <result pre="fibroblastsAging (Albany NY)1020183294330710.18632/aging.10163330428454 78AvedissianS.N.RhodesN.J.NgT.N.H.RaoA.P.BeringerP.M.The potential for QT interval prolongation with" exact="chronic" post="azithromycin therapy in adult cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 79TangF.LiR.XueJ.LanJ.XuH.LiuY.ZhouL.LuY.Azithromycin attenuates"/>
 <result pre="potential for QT interval prolongation with chronic azithromycin therapy in" exact="adult" post="cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 79TangF.LiR.XueJ.LanJ.XuH.LiuY.ZhouL.LuY.Azithromycin attenuates acute radiation-induced lung injury"/>
 <result pre="for QT interval prolongation with chronic azithromycin therapy in adult" exact="cystic fibrosis" post="patientsPharmacotherapy39201971872310.1002/phar.227031045258 79TangF.LiR.XueJ.LanJ.XuH.LiuY.ZhouL.LuY.Azithromycin attenuates acute radiation-induced lung injury in miceOncology"/>
 <result pre="chronic azithromycin therapy in adult cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 79TangF.LiR.XueJ.LanJ.XuH.LiuY.ZhouL.LuY.Azithromycin attenuates" exact="acute" post="radiation-induced lung injury in miceOncology Letter1420175211522010.3892/ol.2017.681 80MadridP.B.PanchalR.G.WarrenT.K.ShurtleffA.C.EndsleyA.N.GreenC.E.KolokoltsovA.DaveyR.MangerI.D.GilfillanLL.BavariS.TangaM.J.Evaluation of ebola"/>
 <result pre="repurposingACS Infect. Dis.1July 10 (7)201531732610.1021/acsinfecdis.5b0003027622822 81RoyJ.PaquetteJ.S.FortinJ.F.TremblayM.J.The immunosuppressant rapamycin represses human" exact="immunodeficiency" post="virus type 1 replicationAntimicrob. Agents Chemother.46November(11)20023447345512384349 82ZhangM.XieM.LiS.GaoY.XueS.HuangH.ChenK.LiuF.ChenL.Electrophysiologic studies on"/>
 <result pre="Dis.1July 10 (7)201531732610.1021/acsinfecdis.5b0003027622822 81RoyJ.PaquetteJ.S.FortinJ.F.TremblayM.J.The immunosuppressant rapamycin represses human immunodeficiency virus" exact="type 1" post="replicationAntimicrob. Agents Chemother.46November(11)20023447345512384349 82ZhangM.XieM.LiS.GaoY.XueS.HuangH.ChenK.LiuF.ChenL.Electrophysiologic studies on the risks and"/>
 <result pre="the 2012 FDA warning on the risk of potentially fatal" exact="heart" post="rhythmsPharmacotherapy40202010711510.1002/phar.235531867748 85AvedissianS.N.RhodesN.J.NgT.N.M.RaoA.P.BeringerP.M.The potential for QT interval prolongation with chronic"/>
 <result pre="fatal heart rhythmsPharmacotherapy40202010711510.1002/phar.235531867748 85AvedissianS.N.RhodesN.J.NgT.N.M.RaoA.P.BeringerP.M.The potential for QT interval prolongation with" exact="chronic" post="azithromycin therapy in adult cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 86FangL.KarakiulakisG.RothM.Are patients"/>
 <result pre="potential for QT interval prolongation with chronic azithromycin therapy in" exact="adult" post="cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 86FangL.KarakiulakisG.RothM.Are patients with hypertension and diabetes"/>
 <result pre="for QT interval prolongation with chronic azithromycin therapy in adult" exact="cystic fibrosis" post="patientsPharmacotherapy39201971872310.1002/phar.227031045258 86FangL.KarakiulakisG.RothM.Are patients with hypertension and diabetes mellitus at"/>
 <result pre="azithromycin therapy in adult cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 86FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="in adult cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 86FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir. Med.8April (4)202010.1016/S2213-2600(20)30116-8e21"/>
 <result pre="(4)202058659010.1007/s00134-020-05985-932125455 88de SimoneG.MancusiC.Speculation is not evidence: antihypertensive therapy and COVID-19Eur." exact="Heart" post="J. Cardiovasc. Pharmacother.1202010.1093/ehjcvp/pvaa021Apr pii: pvaa021 89MazzonM.MercerJ.Lipid interactions during virus"/>
 <result pre="and infectionCell. Microbiol.16October (10)20141493150210.1111/cmi.1234025131438 90RothwellC.LebretonA.Young NgC.LimJ.Y.LiuW.VasudevanS.LabowM.GuF.GaitherL.A.Cholesterol biosynthesis modulation regulates dengue" exact="viral" post="replicationVirology389200981910.1016/j.virol.2009.03.02519419745 91FedsonD.S.RordamO.M.Treating Ebola patients: aâ€™ bottom upâ€™ approach using"/>
 <result pre="COVID-19 infectionmBio11March 20 (2)202010.1128/mBio.00398-20)pii: e00398-20 93CalfeeC.S.DelucchiK.L.SinhaP.MatthayM.A.HackettJ.Shankar-HariM.McDowellC.LaffeyJ.G.Oâ€™KaneC.M.McAuleyD.F.Irish Critical Care Trials Group." exact="Acute respiratory distress syndrome" post="subphenotypes and differential response to simvastatin: secondary analysis of"/>
 <result pre="infectionmBio11March 20 (2)202010.1128/mBio.00398-20)pii: e00398-20 93CalfeeC.S.DelucchiK.L.SinhaP.MatthayM.A.HackettJ.Shankar-HariM.McDowellC.LaffeyJ.G.Oâ€™KaneC.M.McAuleyD.F.Irish Critical Care Trials Group. Acute" exact="respiratory" post="distress syndrome subphenotypes and differential response to simvastatin: secondary"/>
 <result pre="(2)202010.1128/mBio.00398-20)pii: e00398-20 93CalfeeC.S.DelucchiK.L.SinhaP.MatthayM.A.HackettJ.Shankar-HariM.McDowellC.LaffeyJ.G.Oâ€™KaneC.M.McAuleyD.F.Irish Critical Care Trials Group. Acute respiratory distress" exact="syndrome" post="subphenotypes and differential response to simvastatin: secondary analysis of"/>
 <result pre="Acute respiratory distress syndrome subphenotypes and differential response to simvastatin:" exact="secondary" post="analysis of a randomised controlled trialLancet Respir. Med.6September (9)201869169810.1016/S2213-2600(18)30177-230078618"/>
 <result pre="94McAuleyD.F.LaffeyJ.G.Oâ€™KaneC.M.PerkinsG.D.MullanB.TrinderT.J.JohnstonP.HopkinsP.A.JohnstonA.J.McDowellC.McNally; HARP-2C.Investigators; Irish Critical Care Trials Group. Simvastatin in the" exact="acute" post="respiratory distress syndromeN. Engl. J. Med.371October 30 (18)20141695170310.1056/NEJMoa140328525268516 95HussainA.BhowmikB.do"/>
 <result pre="HARP-2C.Investigators; Irish Critical Care Trials Group. Simvastatin in the acute" exact="respiratory" post="distress syndromeN. Engl. J. Med.371October 30 (18)20141695170310.1056/NEJMoa140328525268516 95HussainA.BhowmikB.do Vale"/>
 <result pre="in forensic thanatologyLeg Med (Tokyo).352018121710.1016/j.legalmed.2018.09.003November30232046 97RussoC.V.SaccÃ F.PaternosterM.BuonomoA.R.GentileI.ScottoR.Brescia MorraV.MansuetoG.Post-mortem diagnosis of" exact="invasive pulmonary aspergillosis" post="after alemtuzumab treatment for multiple sclerosisMult. Scler.26January (1)202012312610.1177/135245851881311030882274 98de"/>
 <result pre="forensic thanatologyLeg Med (Tokyo).352018121710.1016/j.legalmed.2018.09.003November30232046 97RussoC.V.SaccÃ F.PaternosterM.BuonomoA.R.GentileI.ScottoR.Brescia MorraV.MansuetoG.Post-mortem diagnosis of invasive" exact="pulmonary" post="aspergillosis after alemtuzumab treatment for multiple sclerosisMult. Scler.26January (1)202012312610.1177/135245851881311030882274"/>
 <result pre="thanatologyLeg Med (Tokyo).352018121710.1016/j.legalmed.2018.09.003November30232046 97RussoC.V.SaccÃ F.PaternosterM.BuonomoA.R.GentileI.ScottoR.Brescia MorraV.MansuetoG.Post-mortem diagnosis of invasive pulmonary" exact="aspergillosis" post="after alemtuzumab treatment for multiple sclerosisMult. Scler.26January (1)202012312610.1177/135245851881311030882274 98de"/>
</results>
